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UV light is an established carcinogen, yet evidence
suggests thatUV-seekingbehavior has addictive fea-
tures. Following UV exposure, epidermal keratino-
cytes synthesize proopiomelanocortin (POMC) that
is processed to melanocyte-stimulating hormone,
inducing tanning. We show that, in rodents, another
POMC-derived peptide, b-endorphin, is coordinately
synthesized in skin, elevating plasma levels after low-
dose UV. Increases in pain-related thresholds are
observed and reversed by pharmacologic opioid
antagonism. Opioid blockade also elicits withdrawal
signs after chronic UV exposure. This effect was
sufficient to guide operant behavioral choices to
avoidance of opioid withdrawal (conditioned place
aversion). These UV-induced nociceptive and behav-
ioral effects were absent in b-endorphin knockout
mice and in mice lacking p53-mediated POMC
induction in epidermal keratinocytes. Although pri-
mordial UVaddiction,mediatedby thehedonicaction
of b-endorphin and anhedonic effects of withdrawal,
may theoretically have enhanced evolutionary vita-
min D biosynthesis, it now may contribute to the
relentless rise in skin cancer incidence in humans.INTRODUCTION
Despite widespread awareness that UV exposure is a major risk
factor for all common cutaneous malignancies, skin cancer inci-
dence relentlessly increases by 3% per year (de Gruijl, 1999;
Gandini et al., 2011; Robinson et al., 1997). UV-seeking behavior
is a recognized risk factor, but it is incompletely understood
whether the popularity of sunbathing represents a biological
addiction or an aesthetic preference for tanned skin. Studies
have reported that many UV seekers meet CAGE and DSM-IV
criteria for a substance-related disorder with respect to UV(Harrington et al., 2011; Kourosh et al., 2010; Lazovich et al.,
2010; Mosher and Danoff-Burg, 2010; Warthan et al., 2005)
and that UV seekers were capable of distinguishing between
true UV and mock treatment in blind tanning bed experiments
(Feldman et al., 2004), and two studies of small cohorts of
frequent tanners revealed that acute administration of the opioid
antagonist naltrexone can induce withdrawal-like symptoms
(Kaur et al., 2005, 2006b). Although amechanism for such addic-
tion has been lacking, these studies are consistent with the
possibility of endogenous opioid-mediated addictive behavioral
effects.
In the cutaneous response to UV exposure, epidermal kerati-
nocytes respond to DNA damage via p53-mediated transcrip-
tional induction of the proopiomelanocortin (POMC) gene (Cui
et al., 2007). POMC is posttranslationally cleaved into biologi-
cally active peptides, one of which is a-melanocyte-stimulating
hormone (a-MSH), which mediates the tanning process by
stimulating adjacent melanocytes to produce the brown/black
pigment eumelanin (D’Orazio et al., 2006). The endogenous
opioid b-endorphin is also posttranslationally generated in skin
by cleavage of the POMC propeptide in response to UV radiation
(Cui et al., 2007; Skobowiat et al., 2011; Slominski and Worts-
man, 2000). b-endorphin is the most abundant endogenous
opioid, with basal plasma levels of 1–12 pM (Bender et al.,
2007; Fassoulaki et al., 2007; Leppa¨luoto et al., 2008), and intra-
venous administration of b-endorphin has been shown to cause
analgesia (Tseng et al., 1976). It binds with high affinity to the
m-opioid receptor (Schoffelmeer et al., 1991), although some
evidence suggests that it may also act through other mecha-
nisms that are, at present, incompletely characterized (Nguyen
et al., 2012). Exogenous opioids with similar mechanisms are
analgesic and have reinforcing properties that make them addic-
tive when administered systemically. Chronic opioid exposure
results in tolerance (increasing dose requirement to achieve
comparable efficacy) and physical dependence (opioid anta-
gonism produces withdrawal). b-endorphin plays a role in anal-
gesia (Ibrahim et al., 2005; Kastin et al., 1979), as well as in the
reinforcement and reward that underlie addiction (Gianoulakis,
2009; Olive et al., 2001; Racz et al., 2008; Roth-Deri et al., 2003;
Trigo et al., 2009). Here, we asked whether UV exposure mayCell 157, 1527–1534, June 19, 2014 ª2014 Elsevier Inc. 1527
A B
C
Figure 1. Plasma b-Endorphin Increases
with Chronic UV Exposure and Parallels
Naloxone-Reversible Changes in Pain
Tolerance
(A) Plasma b-endorphin in C57Bl6 mice receiving
daily UV or mock irradiation (n > 9 for all groups).
Mice were treated twice a week with either
naloxone or saline as indicated. Data are pre-
sented as themean ±SEM, and a two-way ANOVA
analysis with Bonferroni multiple comparisons test
gives p < 0.05 for both UV-treated groups
compared to bothmock-treated groups (duringUV
treatment, days 14–42) and no significant effect of
naloxone treatment within either group.
(B and C) Von Frey thresholds (B) and hot-plate
thresholds (C) in chronically UV-irradiated and
mock-irradiated C57Bl6 mice (mean ± SEM). Half
of each group was pretreated with naloxone
(10 mg/kg) 15 min prior to nociceptive testing,
while the remainder received saline (n = 10 per
group). Analgesic thresholds were further monitored for 2 additional weeks after cessation of UV/mock treatment. Two-way ANOVA with Bonferroni multiple
comparisons test reveals p < 0.0001 for the UV/saline-treated group compared to all other groups during UV treatment, days 9–39).stimulate changes in systemic b-endorphin levels that result in
opioid-related behaviors, including alterations in nociceptive
thresholds, tolerance to exogenous opioids, and dependence,
as measured by withdrawal signs and conditioned place
preference.
RESULTS
Systemic b-Endorphin Elevations following
Chronic UV Exposure
We developed a UV-exposure mouse model in which dorsally
shaved mice received a dose of 50 mJ/cm2 of UVB 5 days per
week for 6 weeks, an empirically derived suberythemic dose
that is approximately equal to 20–30 min of ambient midday
sun exposure in Florida during the summer for a fair-skinned per-
son of average tanning ability (Fitzpatrick skin phototypes 2–3)
(D’Orazio et al., 2006; Technology Planning and Management
Corporation, 2000; US-EPA, 1994). After 1 week, significant
elevations in circulating plasma b-endorphin were observed
(Figure 1A). Circulating b-endorphin levels remained elevated
for the duration of the 6-week exposure regimen and returned
within 7 days to near-baseline levels after cessation of UV expo-
sure. No significant changes in plasma b-endorphin were
observed in mock-UV-treated mice (Figure 1A). Analgesic
thresholds can be increased by peripheral administration of
exogenous opioids or b-endorphin (Kastin et al., 1979). We
quantified mechanical and thermal nociceptive thresholds over
6 weeks of daily UV exposure. Mechanical nociception was
measured by the von Frey test (Kwan et al., 2006), which ex-
poses fibers of increasing tensile strength to the plantar paw
surface to elicit a paw-withdrawal response. Thermal nocicep-
tion was tested using the hot-plate (52C) test (Mogil et al.,
1999), in which time to response (paw licking, paw flutter, or
jumping) wasmeasured. UV-irradiatedmice exhibited significant
increases both in mechanical (Figure 1B) and thermal (Figure 1C)
nociceptive thresholds. These elevated analgesic thresholds
paralleled the UV-induced elevations in plasma b-endorphin1528 Cell 157, 1527–1534, June 19, 2014 ª2014 Elsevier Inc.(Figure 1A). Mock-treated control mice displayed no significant
elevations in pain thresholds (Figures 1B and 1C). Treatment
with naloxone, an opioid antagonist, 15 min prior to analgesic
testing suppressed the UV-induced increases in mechanical
and thermal nociceptive thresholds (Figures 1B and 1C) despite
maintained elevations in plasma b-endorphin (Figure 1A). These
data demonstrate opioid receptor-mediated analgesia as a
consequence of UV that parallels the elevation of circulating
blood b-endorphin.
Quantifiable Opioid-Mediated Behaviors Occur
with Chronic UV Exposure
Exogenous opioids produce a dose-dependent, m-opioid recep-
tor-mediated contraction of the sacrococcygeus dorsalis mus-
cle at the tail base in rodents, resulting in rigidity and elevation
of the tail, a phenomenon called ‘‘Straub tail’’ (Bilbey et al.,
1960). Straub tail was evident in UV-irradiated mice by the
second week of daily UV exposure, persisted for the 6 week
exposure regimen, and diminished over 2 weeks after cessation
of UV (Figure 2A). Treatment with the opioid antagonist naloxone
(day 23 of the UV-exposure regimen) reversed the Straub tail
phenotype (Figures 2B and 2C).
Opioid Tolerance and Physical Dependence
after Chronic UV Exposure
We next asked whether chronic UV exposure may be accom-
panied by detectable opioid dependence, in which opioid
cessation or antagonism produces withdrawal symptoms, and
tolerance in which increasing doses are required to achieve
comparable analgesia (Drdla et al., 2009). Following chronic
daily UV exposure, administration of naloxone elicited many
of the classic murine signs of opioid withdrawal (wet dog shake,
paw tremor, teeth chatter, and rearing) (Olson et al., 2006)
(Figure 3A).
Because the magnitude of the measured withdrawal symp-
toms, while significant, was smaller than that commonly ob-
served with exogenously administered opioids (Broseta et al.,
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Figure 2. Straub Tail in UV-Irradiated Mice Is Reversed by Naloxone
(A) Straub tail in C57Bl6mice over the course of 42 days of UV irradiation (n = 13) ormock irradiation (n = 6). Data are presented as themean ±SEM for days 10–37;
p < 0.0001 by two-way ANOVA analysis.
(B) Straub tail in at day 17 before (Pre) and 15 min after (Post) injection of naloxone (n = 7) or saline (n = 6). Data are presented as the mean ± SEM; p < 0.001 by
Student’s t test.
(C) Representative animals from each group in part (B). The beginning of black fur regrowth produces a patchy appearance.2002), we wished to determine whether these withdrawal signs
would be sufficient to elicit alterations in proactive/operant
behavioral choices. We utilized a conditioned place prefer-
ence/aversion assay (CPP; Skoubis et al., 2001; Weitemier
and Murphy, 2009) to test whether a specific environment,
paired with naloxone administration during conditioning, would
be avoided in favor of a different environment paired with
a neutral stimulus (saline) during conditioning in chronically
UV-irradiated animals. Due to the kinetics of the UV response,
we chose to use naloxone as it allowed an acute effect of
limited duration. Naloxone induces conditioned place aver-
sion in exogenous opioid-dependent mice (Glass et al.,
2008; Kenny et al., 2006). Following conditioning, mice are
permitted to move freely between the two environments, and
changes in place preference are measured in the absence of
additional naloxone or saline administration. Our conditioning
environments were black and white boxes with dim and
bright lighting, respectively, and to minimize apparatus bias,
we assigned the black box as the naloxone (withdrawal stim-
ulus)-paired box and the white box as the saline (neutral stim-
ulus)-paired box, as rodents prefer dark environments to
light environments in the absence of conditioning (Roma and
Riley, 2005).
We observed that chronically UV-irradiated mice conditioned
with naloxone in the black box avoided the black box in
postconditioning preference testing. Naloxone conditioninghad no effect on mock-treated (non-UV-irradiated) control
mice, and saline conditioning in the black box had no effect on
UV-irradiated or mock-treated mice (Figure 3B). Here, naloxone
was sufficient to induce conditioned place aversion in UV-irradi-
ated mice, suggesting that chronic UV exposure imparts an
opioid-like physical dependence of sufficient magnitude to guide
proactive behavior choices.
To test for the other principal feature of chronic opioid expo-
sure, tolerance, after chronic UV treatment, we asked whether
there is cross-tolerance between chronic UV exposure and
morphine, altering the dose required to produce analgesia
(Mao et al., 2000). After chronic UV exposure, mice required
significantly higher doses of morphine than mock-treated con-
trols to achieve comparable thermal analgesia in the hot-plate
test, as reflected by a rightward shift in the dose-response
curve and an increase in half-maximal effective concentration
from 57 mg/kg in the mock-treated group to 270 mg/kg in the
UV-exposed group (Figure 3C). The analgesic effect of UV
exposure that we detected could be a result of systemic
b-endorphin acting both through the peripheral nervous system
and CNS, but the withdrawal effects and conditioned place
aversion point to a CNS effect. It has been reported that
radiolabeled b-endorphin peptides cross the blood-brain
barrier (Banks and Kastin, 1990). To test whether it is plausible
that skin-derived b-endorphin may cause central effects,
we decided to assess whether peripherally administeredCell 157, 1527–1534, June 19, 2014 ª2014 Elsevier Inc. 1529
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Figure 3. Chronically UV-Exposed Mice
Show Symptoms of Opioid Dependence
(A) Signs of opioid withdrawal in mice under
experimental conditions described in the figure:
UV/saline (n = 9), mock/saline (n = 7), UV/naloxone
(n = 15), and mock/naloxone (n = 7). Data are
presented as the mean ± SEM; *p < 0.05
compared to UV/saline group by two-way ANOVA
with Bonferroni multiple comparisons test.
(B) Conditioned place aversion testing in UV-
treated mice conditioned to the naloxone-paired
box (black box) with an injection of naloxone or
saline (white box) following 42 days of UV or mock
treatment. Mice were permitted to freely move
between naloxone-paired and saline-paired
boxes prior to (pretest, n = 8) and after 4 days of
conditioning (test), and place preferences were
assessed as change in time spent in the naloxone-
paired box (postconditioning  preconditioning).
Data are presented as the mean ± SEM, and
p values were generated by two-way ANOVA with
Bonferroni multiple comparisons test.
(C) Morphine dose-response curves in mice
following 42 days of UV irradiation (n = 31) or mock
exposure (n = 29). Data are presented as the
mean ± SEM; p < 0.0001 by two-way ANOVA.
(D) Conditioned place-preference testing in mice
administered intravenous b-endorphin or saline
through the tail vein. Mice were conditioned to b-endorphin (n = 6) or saline (n = 8) in the white box and saline in the black box. Place preferences were assessed
as change in time spent in the white (b-endorphin)-paired box, postconditioning  preconditioning. Data are presented as the mean ± SEM; p = 0.0145
by Student’s t test.b-endorphin injected intravenously into the tail vein could cause
conditioned place preference. To attempt to match an acute
intravenously administered drug dose with a chronic elevation,
we chose a bendorphin concentration reported to cause a
similar analgesic response to that we observed in our UV-expo-
sure experiments, (Tseng et al., 1976). b-endorphin or saline
was injected into the tail vein of mice that were then conditioned
to the white side of the CPP apparatus. The mice that had been
conditioned with saline spent less time in the white box on the
final day than on the initial day (Figure 3D); this was expected,
as mice naturally prefer a dark environment. However, the
mice that had received b-endorphin in the white box spent
more time in the white box after conditioning (Figure 3D), indi-
cating a conditioned place preference for the environment
where they experienced b-endorphin. This shows that peripher-
ally administered b-endorphin can cause conditioned place
preference, presumably through the CNS.
These findings show that chronic UV exposure stimulates and
sustains sufficient endogenous opioid release and opioid recep-
tor activity to develop both opioid tolerance and physical
dependence.
b-Endorphin Knockout Abolishes UV-Induced
Behavioral Changes
To specifically examine the functional requirement for b-endor-
phin in these UV-associated behavioral changes, we employed
b-endorphin knockout mice (lacking the C terminus of the
POMC gene) (Rubinstein et al., 1996) and found that they ex-
hibited no significant changes in thermal or mechanical nocicep-1530 Cell 157, 1527–1534, June 19, 2014 ª2014 Elsevier Inc.tive thresholds with chronic UV exposure (Figures 4A and 4B).
The b-endorphin null mice also failed to develop signs of opioid
withdrawal (Figure 4C) and, when subjected to the conditioned-
place aversion test, exhibited no measurable change in place
preference (Figure 4D).
Keratinocyte Expression of p53 Is Required for Elevated
b-Endorphin Levels and Pain Thresholds
The UV-induced cutaneous upregulation of POMC, the pre-
cursor to both a-MSH and b-endorphin, is mediated by the
tumor suppressor p53, which directly activates POMC gene
transcription in keratinocytes (Cui et al., 2007). To test whether
keratinocyte expression of p53 is required for UV-mediated
increases in circulating b-endorphin, we crossed a mouse
strain with a floxed allele of p53 with a strain containing cre
under the control of the keratin 14 promoter, which is selec-
tive to keratinocytes. We subjected the p53fl/fl K14cre and
control p53+/+ K14cre mice to the UV-irradiation regimen and
assayed plasma b-endorphin levels, mechanical nociception,
and naloxone-induced conditioned place aversion. Consistent
with the known role of p53 in the tanning response, there
was an absence of any tanning on the ears of the p53fl/fl
K14cre animals (Figure 5A). Further, we observed no increase
in circulating b-endorphin (Figure 5B) or in mechanical nocicep-
tion threshold (Figure 5C). Moreover, the K14cre control mice
showed significant naloxone-conditioned place aversion com-
pared to the p53fl/fl K14cre animals (Figure 5D). These data
indicate that keratinocyte-derived b-endorphin is a key factor
in mediating UV-induced addiction.
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Figure 4. Genetic Lack of b-Endorphin
Abolishes Changes in Pain Tolerance and
Opioid Dependence with Chronic UV Expo-
sure
(A and B) Von Frey test (A) and thermal analgesic
thresholds (B) in wild-type (n = 11) and
b-endorphin/ (n = 13) mice over 35-day UV
exposure. Data are presented as the mean ± SEM;
*p < 0.05 by two-way ANOVA with Bonferroni
multiple comparisons test.
(C) Signs of naloxone-precipitated opioid with-
drawal in control and b-endorphin null mice after
6 weeks of UV exposure. Data are presented as
the mean ± SEM; *p < 0.0001 compared to the
b-endorphin//naloxone group by two-way
ANOVAwith Bonferroni multiple comparisons test;
n > 7 for all groups.
(D) Conditioned place aversion testing in UV-
treated control and b-endorphin null mice condi-
tioned to the naloxone-paired box (black box) with
an injection of naloxone or saline. All mice were
conditioned to saline in the white box; n > 10 for all
groups. Mice were permitted to freely move be-
tween naloxone-paired and saline-paired boxes
prior to and after 4 days of conditioning, and place
preferences were assessed as change in time
spent in the naloxone-paired box (postcondition-
ing  preconditioning). Data are presented as the
mean ± SEM; p valueswere generated by two-way
ANOVA with Bonferroni multiple comparisons test.DISCUSSION
Our findings suggest that repeated UV exposure produces an
opioid receptor-mediated addiction due to elevations in circu-
lating b-endorphin, leading to increased nociceptive thresholds
that are reversed by naloxone or ablated in b-endorphin null
mice. Measurable withdrawal symptoms are elicited by nalox-
one, and proactive place-preference behaviors were strongly
induced, based on prior conditioning between opioid receptor
antagonism and cage color. Further, a skin-specific knockout
of p53, a critical step in the UV-response pathway, prevented
both the b-endorphin elevation and the behavioral responses.
There remains a formal possibility that skin-specific p53 knock-
out could affect b-endorphin expression outside of the skin.
While these studies were performed in a nocturnal and furred
animal model, significant evidence supports a strong relation-
ship between UV exposure and addictive behaviors in humans
(Feldman et al., 2004; Harrington et al., 2011; Kaur et al., 2005,
2006b; Kourosh et al., 2010; Mosher and Danoff-Burg, 2010;
Warthan et al., 2005; Zeller et al., 2006). Several small studies
have attempted to measure b-endorphin changes with UV expo-
sure in humans (Gambichler et al., 2002; Kaur et al., 2006a;
Levins et al., 1983; Wintzen et al., 2001), with some showing
UV-induced elevations and others not, although significant con-
founding variables complicate such measurements, such as
diurnal variations in b-endorphin (McMurray et al., 1990) and
stressors that also influence b-endorphin levels (Aravich et al.,
1993; Gianoulakis et al., 1996; Petraglia et al., 1990; Welch
et al., 1996). While the effects of sunscreen have not been re-
ported in this context, it does appear likely that sunscreen use
would protect against UV-induced addictive behaviors.Despite the carcinogenicity of UV and hence the serious mal-
adaptive consequences of addiction to UV exposure, our results
may also imply a potential evolutionary benefit of an endogenous
mechanism that reinforces UV-seeking behavior, one that may
operate by creating an opioid-mediated hedonic experience fol-
lowed by dependence on the behavior to avoid the anhedonic
consequences of withdrawal. Further studies may shed light
on the site/sites of b-endorphin action within the brain and
whether the brain regions and neuronal subpopulations involved
in sun-seeking behavior are the same as those involved the
analgesic response or in exogenous opioid addiction. A recent
study has shown activation of known reward centers in the
brains of volunteers during UV exposure (Harrington et al., 2012).
The current studies suggest that UV exposure is biologically
addictive but dangerous due to UV’smutagenic activities toward
formation of all common forms of skin cancer. This calls into
question the perceived safety of tanning beds and current
benign views of indoor tanning, reflected in the United States’
current Food and Drug Administration classification of UV-emit-
ting devices as class I and therefore minimally regulated. It may
be necessary, therefore, to more proactively protect individuals,
including teens, from the risks of an avoidable, potentially life-
threatening exposure and to view recreational tanning and
opioid drug abuse as engaging in the same biological pathway.EXPERIMENTAL PROCEDURES
Mice
All mice used were on a C57Bl/6 background. For select experiments, mice
with homozygous deletion of the C terminus of the POMC gene, resulting in
lack of b-endorphin (b-endorphin/) (Rubinstein et al., 1996), and mice withCell 157, 1527–1534, June 19, 2014 ª2014 Elsevier Inc. 1531
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Figure 5. Keratinocyte Expression of p53 Is
Required for Elevated b-Endorphin Levels
and Pain Thresholds
(A) Representative K14cre and p53fl/fl K14cre
mice after 4 weeks of daily UV treatment.
(B) Plasma b-endorphin in mice in K14cre (n = 10)
and p53fl/fl K14cre (n = 9) mice receiving daily UV
irradiation. Data are presented as the mean ±
SEM; *p < 0.05 by two-way ANOVA analysis with
Bonferroni multiple comparisons test.
(C) Mechanical analgesic thresholds in K14cre
and p53fl/fl K14cre mice over 13 days of UV
exposure. Data are presented as the mean ± SEM;
*p < 0.05 by two-way ANOVA with Bonferroni
multiple comparisons test.
(D) K14cre and p53fl/fl K14cre mice were condi-
tioned to naloxone in the black box after 3 weeks
of daily UV exposure. Place preferences were as-
sessed as change in time spent in the naloxone-
paired box. Data are presented as the mean ±
SEM; p = 0.0317 by Student’s t test. The change in
time spent in the black box was not significant
when the postconditioning and preconditioning
timeswere compared by Student’s t test (p = 0.26).a floxed allele of p53 (Marino et al., 2000) and a keratin 14 promoter-driven Cre
recombinase strain (Dassule et al., 2000) were used. All animal experiments
were performed in accordance with institutional policies and Institutional
Animal Care and Use Committee-approved protocols.
UV Irradiation and Blood Draws
Mice were dorsally shaved 2 days prior to the start of radiation exposure, then
exposed to 50 mJ/cm2/day of UVB, an empirically determined suberythematic
dose, 5 days per week (Monday–Friday) for 6 weeks. Micewere reshaved once
every 2 weeks if there were patches of fur regrowth.
For blood draws, mice were placed in a standard restrainer and tail vein
blood was collected in EDTA microvette tubes containing 0.6 TIU aprotinin.
Mice underwent blood draws prior to the stat of radiation exposure, once
per week during the radiation exposure regimen, and once per week for
2 weeks following cessation of the UV regimen. Blood was drawn in the
mornings prior to radiation exposure on Fridays.
Tubes of collected blood were maintained on ice until centrifugation at
3,500 rpm for 20 min at 4C. Plasma was isolated, and samples were stored
at 80C until b-endorphin measurement. b-endorphin was quantified by
radioimmunoassay (Phoenix Pharmaceuticals).
Straub Tail Measurement
Straub tail measurement was performed as described previously (Bilbey et al.,
1960). Scoring was on a scale of 0–2 according to the angle of elevation of the
tail from the horizontal plane (0 = tail relaxed and no elevation; 1 = tail is rigid
and elevated 1–10 from horizontal; 1.5 = 11–45 elevation and rigidity at
the base of the tail; 2 = 46–90 elevation with rigidity at the base of the tail).
For each time point, each mouse was scored every 10 s for 1 min, and the final
score was the average of these six values. Mice undergoing the 6-week
UV-exposure regimen or mock treatment were scored prior to the start of
the regimen, once perweek during the regimen, and once perweek for 2weeks
following cessation of UV/mock treatment. On day 23 of the regimen after
weekly Straub tail scoring, mice were injected intraperitoneally (i.p.) with
either 10 mg/kg naloxone hydrochloride (Sigma) or saline. Mice underwent
Straub tail scoring again 15 min following injection.1532 Cell 157, 1527–1534, June 19, 2014 ª2014 Elsevier Inc.Analgesic Threshold Testing
Mice underwent mechanical and thermal anal-
gesic testing during UV/mock treatment regimens
using the von Frey test (Kwan et al., 2006) and thehot-plate test, respectively (Mogil et al., 1999). In the von Frey test, mice were
placed in individual enclosures on an elevated wire mesh rack and the plantar
surface of the left hind paw was serially poked with fibers of increasing tensile
strength (ten times per fiber at a rate of 1/second) until a paw withdrawal
response was elicited on two out of ten pokes. In the hot-plate test, mice
were placed on a 52C hot plate and time to response (paw flutter, paw licking,
or jumping) was measured.
Mice were habituated to the wire mesh rack for 30 min per day and to the
hot plate at room temperature for 2 min per day for 3 days prior to measuring
baseline nociceptive thresholds. Mice underwent nociceptive testing twice
per week on nonconsecutive days during and for 2 weeks following cessation
of UV/mock treatment. Mice received an intraperitoneal injection of 10 mg/kg
naloxone or saline 15 min prior to nociceptive testing.
Somatic Symptoms of Opiate Withdrawal
Mice that had undergone 6 weeks of daily UV exposure or mock exposure
were injected i.p. with either 2 mg/kg naloxone or saline, and signs of opioid
withdrawal were tabulated as described elsewhere (Olson et al., 2006). Mice
were observed in an open-topped Plexiglas 30 cm 3 15 cm 3 15 cm rectan-
gular container for 25 min each following injection, and signs of opioid with-
drawal were tabulated. Wet dog shake, teeth chatter, and bouts of grooming
were measured as occurrence in each 15 s interval. Individual rearing events
were counted. Number of fecal pellets at the end of the 25 min interval was
used to quantify diarrhea.
Conditioned Place Aversion Testing
The apparatus used consisted of a box with black interior and dim lighting and
a box with white interior and bright lighting connected by a smaller gray
‘‘neutral’’ box, and procedures were followed as described previously (Skou-
bis et al., 2001; Weitemier and Murphy, 2009). Mice that had undergone
6weeks of daily UV exposure ormock exposure were tested for baseline place
preferences prior to conditioning (10 min testing time per mouse). Over the
following 4 days, conditioning took place in which mice were either condi-
tioned with naloxone (10 mg/kg injection i.p.) or saline (injection i.p.) in the
black box, and all animals were conditioned with saline (injection i.p.) in the
white box. Conditioning time in each box was 30 min following injection. For
each animal, there were 4 hr between conditioning in one box and condition
in the other box each day. On the day following the final day of conditioning,
place preferences were again tested (postconditioning, 10 min testing time
per mouse).
Morphine Cross-Tolerance Testing
Morphine dose-response curves in the hot-plate test were measured as
described elsewhere (Mao et al., 2000) in mice that had undergone 6 weeks
of UV exposure or mock treatment. Morphine was injected at a starting dose
of 0.02 mg/kg i.p. and was increased logarithmically in cumulative dose incre-
ments of 0.3 log units. Thermal analgesic thresholds were tested 15 min after
each morphine injection until there was failure to respond in the hot-plate test
(cutoff time was 20 s) or until there was no change in response time from one
dose to the next. There were 30 min between injections and 30 min between
hot-plate testings for each mouse. Percent of maximal effect was calculated
based on the equation: (test latency  baseline latency) / (maximal latency 
baseline latency) 3 100% (Mao et al., 2000).AUTHOR CONTRIBUTIONS
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